A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for the Maintenance Treatment of Anemia in Kidney Transplant Recipients.

Condition:   AnemiaInterventions:   Drug: Darbepoetin alfa;   Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor:   Hoffmann-La RocheCompleted - verified May 2015

Source: ClinicalTrials.gov - January 18, 2008 Category: Research Source Type: clinical trials